Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SINOVAC BIOTECH LTD.

(SVA)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sinovac Biotech : Pfizer study to vaccinate whole Brazilian town against COVID-19

10/06/2021 | 02:48pm EST

BRASILIA, Oct 6 (Reuters) - Pfizer Inc will study the effectiveness of its vaccine against COVID-19 by inoculating the entire population over the age of 12 in a town in southern Brazil, the company said on Wednesday.

The study will be conducted in Toledo, population 143,000, in the west of Parana state, together with Brazil's National Vaccination Program, local health authorities, a hospital and a federal university.

Pfizer, which developed the vaccine with German partner BioNTech SE, said the purpose was to study transmission of the coronavirus in a "real-life scenario" after the population has been vaccinated.

"The initiative is the first and only of its kind to be undertaken in collaboration with the pharmaceutical company in a developing country," Pfizer said.

A similar study was conducted by the Butantan Institute, one of Brazil's leading biomedical research centers, in the smaller town of Serrana, in Sao Paulo state. That trial tested the CoronaVac shot developed by China's Sinovac Biotech Ltd.

In May, Butantan said mass vaccination had reduced COVID-19 death by 95% in the town with a population of 45,644 people. The institute is considering extending the study for a third dose.

"Here we believe in science and we lament the almost 600,000 deaths from COVID-19 in Brazil," Toledo Mayor Beto Lunitti said at a news conference announcing the Pfizer study.

There is little anti-vaccine resistance in Toledo, where 98% of the population have had a first dose, mainly of the Pfizer/BioNTech vaccine. AstraZeneca's COVID-19 shot and Sinovac's have also been used there, municipal health secretary Gabriela Kucharski said, adding that 56% are fully vaccinated.

Regis Goulart, a researcher at Porto Alegre's Moinhos de Vento Hospital taking part in the study, said its aim was to validate the real-world efficacy and safety of the vaccine seen in clinical trials.

The observational study also will provide an opportunity to do long-term monitoring for up to one year of participants, helping to answer lingering questions such as the duration of vaccine protection against COVID-19 and new virus variants, Goulart said. (Reporting by Anthony Boadle; Editing by Jason Neely, Mark Porter and Bill Berkrot)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.94% 8336 Delayed Quote.14.84%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.0.00%
All news about SINOVAC BIOTECH LTD.
11/23Mexico eyes COVID-19 vaccine booster shots, especially for older adults
RE
11/20Hong Kong authorises Sinovac vaccine for children aged 3-17
RE
11/10Preliminary Results Show SINOVAC's COVID-19 Vaccine Demonstrates Good Safety Profile Am..
PU
11/09Preliminary Results Show SINOVAC's COVID-19 Vaccine Demonstrates Good Safety Profile Am..
BU
11/09Sinovac Biotech Ltd. Announces New Preliminary Data on its Inactivated COVID-19 Vaccine..
CI
11/08UK to add China's Sinovac, India's Covaxin to approved vaccine list
RE
11/03Indian home-grown COVID-19 shot wins WHO emergency use approval
RE
11/03Indian home-grown COVID-19 shot wins WHO emergency use approval
RE
11/03Hong Kong to launch COVID-19 booster campaign from next week
RE
10/30China's Xi calls for COVID-19 vaccine mutual recognition
RE
More news
Financials (USD)
Sales 2020 511 M - -
Net income 2020 110 M - -
Net cash 2020 1 040 M - -
P/E ratio 2020 6,66x
Yield 2020 -
Capitalization 642 M 642 M -
EV / Sales 2019 1,86x
EV / Sales 2020 -0,78x
Nbr of Employees 1 959
Free-Float 33,5%
Chart SINOVAC BIOTECH LTD.
Duration : Period :
Sinovac Biotech Ltd. Technical Analysis Chart | SVA | AGP8696W1045 | MarketScreener
Income Statement Evolution
Managers and Directors
Wei Dong Yin Chairman, President, CEO, Secretary & MD
Nan Wang CFO & Vice President-Business Development
Qiang Gao Chief Operating Officer & Vice President
Yuk Lam Lo Independent Director
Jian Li Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SINOVAC BIOTECH LTD.0.00%642
CSL LIMITED10.18%101 196
WUXI BIOLOGICS (CAYMAN) INC.0.58%56 285
SAMSUNG BIOLOGICS CO.,LTD.5.33%48 100
ALEXION PHARMACEUTICALS, INC.16.81%40 336
BIOGEN INC.-0.80%35 680